

Philip Eg Aylward

List of Publications by Citations

Source: <https://exaly.com/author-pdf/4961522/philip-eg-aylward-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

5
papers

73
citations

4
h-index

7
g-index

7
ext. papers

128
ext. citations

8.2
avg, IF

1.3
L-index

#	Paper	IF	Citations
5	Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial. <i>European Heart Journal</i> , 2020 , 41, 4245-4255	9.5	44
4	Extent of coronary artery disease and outcomes after ticagrelor administration in patients with an acute coronary syndrome: Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. <i>American Heart Journal</i> , 2014 , 168, 68-75.e2	4.9	12
3	Invasive and antiplatelet treatment of patients with non-ST-segment elevation myocardial infarction: Understanding and addressing the global risk-treatment paradox. <i>Clinical Cardiology</i> , 2019 , 42, 1028-1040	3.3	9
2	Use of ticagrelor alongside fibrinolytic therapy in patients with ST-segment elevation myocardial infarction: Practical perspectives based on data from the TREAT study. <i>Clinical Cardiology</i> , 2018 , 41, 1322-1327 ⁶	3.3	6
1	Inhibition of p38 MAP kinase in patients with ST-elevation myocardial infarction - findings from the LATITUDE-TIMI 60 trial. <i>American Heart Journal</i> , 2022 , 243, 147-157	4.9	1